NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Waaree Renewable Bags 300MW/450MWp Solar EPC Order from Subsidiary
Waaree Renewable Technologies Limited (WAAREERTL) has secured a Letter of Award (LOA) for a 300MW/450MWp ground-mount solar project. The contract encompasses Engineering, Procurement, and Construction (EPC) services along with two years of Operation and Maintenance (O&M). The project is awarded by its subsidiary, Sunsational Power Private Limited, and is scheduled for completion within the financial year 2026-27. While it is a related party transaction, the company states it is conducted at arm's length.
முக்கிய அம்சங்கள்
Secured EPC contract for a 300MW/450MWp ground-mount solar project.Includes two years of Operation & Maintenance (O&M) services post-commissioning.Project execution is scheduled for completion during the financial year 2026-27.The order is from Sunsational Power Private Limited, a wholly-owned subsidiary of the company.
👀 கவனிக்க வேண்டியவை
Investors should view this as a boost to the company's order book and revenue visibility for FY27, though they should monitor the consolidated margin impact given it is an intra-group contract.
Hindware Home Innovation Increases Stake in Hintastica to 96.6% via 1.5 Cr Share Allotment
Hindware Home Innovation Limited has successfully increased its ownership in its subsidiary, Hintastica Private Limited (HPL), to 96.6%. This follows the allotment of 1,50,00,000 equity shares to the company under HPL's Rights Issue on June 4, 2026. The move represents a significant consolidation of control and capital infusion into the subsidiary. This update follows the initial disclosure regarding the investment made on June 3, 2026.
முக்கிய அம்சங்கள்
Allotment of 1,50,00,000 equity shares in Hintastica Private Limited (HPL) to Hindware Home Innovation.Hindware's total shareholding in HPL has increased to 96.6% of the paid-up share capital.The allotment was finalized during HPL's board meeting held on June 4, 2026, at 4:30 P.M.The transaction was conducted via a subscription to a Rights Issue.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic consolidation of a subsidiary; monitor HPL's future performance to see how this capital infusion drives growth for the parent company.
Thyrocare to Hold 26th AGM on June 30; Sets June 23 as Record Date for Final Dividend
Thyrocare Technologies has scheduled its 26th Annual General Meeting (AGM) for June 30, 2026, to discuss the FY 2025-26 Annual Report. The company has fixed June 23, 2026, as the record date for determining shareholder eligibility for the final dividend. Shareholders can participate in remote e-voting between June 26 and June 29, 2026. Dividend payments are expected to be processed on or before July 29, 2026.
முக்கிய அம்சங்கள்
26th Annual General Meeting scheduled for June 30, 2026, at 11:00 A.M. IST.Record date for final dividend eligibility is Tuesday, June 23, 2026.Dividend payment to be completed on or before Wednesday, July 29, 2026.E-voting period starts June 26, 2026, and ends June 29, 2026.Annual Report for FY 2025-26 and AGM Notice have been made available via digital links.
👀 கவனிக்க வேண்டியவை
Investors seeking the final dividend should ensure they hold shares by the June 23 record date. Shareholders are also encouraged to review the Annual Report to evaluate the company's financial health and strategic direction.
Thyrocare FY26 Revenue Grows 21% to ₹829 Cr; PAT Surges 79% to ₹163 Cr; AGM on June 30
Thyrocare Technologies delivered a robust performance in FY 2025-26, with revenue from operations increasing 21% YoY to ₹829.04 crore. Profit After Tax (PAT) witnessed a massive 79% jump to ₹162.85 crore, driven by operational efficiencies and network expansion. The company expanded its lab footprint to 41 locations and its test menu to over 1,275 tests. Additionally, the company declared a dividend of ₹9.33 per share (restated for the 2:1 bonus issue) and successfully integrated Think Health for home ECG services.
முக்கிய அம்சங்கள்
Revenue from operations grew 21% YoY to ₹829.04 crore in FY26 compared to ₹687.35 crore in FY25.Profit After Tax (PAT) surged by 79% to ₹162.85 crore, up from ₹90.75 crore in the previous year.Expanded laboratory network to 41 labs (including 7 new labs) and increased test menu to 1,275+ tests.EBITDA increased by 34% YoY to ₹255.88 crore with a significant improvement in margins.Proposed dividend of ₹9.33 per share, adjusted for the 2:1 bonus issue completed during the fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should note the strong recovery in profitability and aggressive network expansion. The company's shift toward specialized diagnostics and home-based services like ECG makes it a competitive player in the diagnostic sector; hold for long-term growth.
Madras High Court Vacates Asset Alienation Injunction Against CARE Ratings
The Madras High Court has vacated an injunction order dated February 1, 2023, which had previously restrained CARE Ratings from alienating its assets. The vacation of this order on June 3, 2026, follows the company's compliance with court requirements to provide adequate security. This development restores the company's full control over its asset base, although the security was provided without prejudice to the company's ongoing legal appeals.
முக்கிய அம்சங்கள்
Madras High Court vacated the injunction restraining asset alienation on June 3, 2026.The original injunction had been in place since February 1, 2023, pending provision of security.CARE Ratings complied with the security requirements to facilitate the lifting of the restriction.The company received the formal court order on June 4, 2026.Compliance was performed without prejudice to the company's rights in its ongoing appeals.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that removes a significant legal restriction on the company's balance sheet flexibility. Continue to monitor the final outcome of the underlying legal appeals.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Religare Enterprises Limited has allotted 83,43,263 equity shares following the conversion of warrants by five key investors, including Ashish Dhawan and JM Financial Credit Solutions. The company received the remaining 75% consideration amounting to Rs 147.05 crore, with the total issue price fixed at Rs 235 per share (including a premium of Rs 225). Consequently, the company's paid-up equity share capital has increased to Rs 341.23 crore, comprising 34,12,33,742 shares. These new shares will rank pari passu with existing shares but are subject to regulatory lock-in periods.
முக்கிய அம்சங்கள்
Allotment of 83,43,263 equity shares of face value Rs 10 at a premium of Rs 225 per share.Receipt of Rs 147.05 crore representing the final 75% payment for warrant conversion.Key allottees include JM Financial Credit Solutions (25 lakh shares) and Ashish Dhawan (17 lakh shares).Total paid-up equity capital increased from Rs 332.89 crore to Rs 341.23 crore.The warrants were originally issued via preferential allotment following shareholder approval in August 2025.
👀 கவனிக்க வேண்டியவை
Investors should note the successful capital infusion and the participation of prominent investors, which signals confidence in the company's long-term prospects. While this leads to equity dilution, the strengthened balance sheet is a positive indicator for future growth.
TTK Healthcare Sets July 17, 2026, as Record Date for Dividend and 68th AGM
TTK Healthcare Limited has announced July 17, 2026, as the record date for determining shareholder eligibility for its upcoming dividend and voting rights. The company's 68th Annual General Meeting (AGM) is scheduled to take place on July 24, 2026, at 12:00 PM via video conferencing. Shareholders must hold the stock by the record date to be eligible for the dividend payout and to participate in the voting process for corporate resolutions.
முக்கிய அம்சங்கள்
Record date for dividend and voting rights fixed for July 17, 2026.68th Annual General Meeting (AGM) scheduled for July 24, 2026, at 12:00 PM.AGM to be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).Shareholders listed as of the cut-off date (July 17) will be eligible for the dividend distribution.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 17 record date. Existing shareholders should also prepare to participate in the virtual AGM to stay informed on company governance.
Hindware Home Innovation to Acquire 100% Stake in Hintastica JV for ₹2.79 Crore
Hindware Home Innovation Limited (HHIL) is transitioning its joint venture, Hintastica Private Limited, into a wholly-owned subsidiary by acquiring the remaining 50% stake from Atlantic for approximately ₹2.79 crore. HHIL will also invest ₹15 crore via a rights issue to provide working capital and has approved a ₹25 crore corporate guarantee for the entity. Hintastica, which focuses on the water heater business, reported a turnover of ₹39.72 crore in FY26, reflecting a decline from ₹58.87 crore in FY25 following the divestment of its manufacturing facility.
முக்கிய அம்சங்கள்
Acquisition of 5,48,787 equity shares from Atlantic for an aggregate consideration of ₹2,78,83,867.Investment of ₹15 crore in Hintastica through a rights issue to capitalize the entity for working capital needs.Hintastica will transition from a joint venture to a 100% wholly-owned subsidiary of HHIL.HHIL to extend a corporate guarantee of ₹25 crore as security for Hintastica's working capital facilities.Hintastica's turnover has declined from ₹59.50 crore in FY24 to ₹39.72 crore in FY26 following its shift to a distribution-led model.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of the water heater business and whether the shift to a distribution-led model can reverse the recent revenue decline and improve margins.
Amara Raja Q4 FY26 Revenue Rises 15% to ₹3,530 Cr; Plans ₹1,700 Cr Capex for FY27
Amara Raja Energy & Mobility reported a 15% YoY revenue growth in Q4 FY26, reaching ₹3,530 crores, primarily driven by a 30% surge in 4-wheeler OEM volumes. While the core Lead Acid business maintained healthy adjusted EBITDA margins of 12.3%, consolidated margins were slightly diluted to 10.8% due to investments in the New Energy segment. The company is aggressively expanding its lithium-ion capabilities, having supplied over 1 GWh of packs in FY26 and planning a massive ₹1,500-₹1,700 crore capex for FY27 to fund its Giga factory and storage solutions.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated revenue grew 15% YoY to ₹3,530 crores, with full-year FY26 revenue at ₹13,814 crores.4-wheeler OEM volumes surged by over 30%, while tubular battery volumes grew by 35% during the quarter.New Energy business contributed ₹280 crores in Q4, with total investment in the subsidiary reaching ₹1,500 crores.Company projected a significant FY27 capex of ₹1,500-₹1,700 crores, with ₹1,100-₹1,200 crores dedicated to New Energy projects.Adjusted Lead Acid business EBITDA margin stood at 12.3% despite rising raw material costs and geopolitical export headwinds.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition toward New Energy and its ability to maintain lead-acid margins through price hikes. The heavy capex cycle for the Giga factory indicates long-term growth potential but may weigh on short-term free cash flows.
TTK Healthcare FY26 Revenue Up 7% to ₹857 Cr; Recommends ₹10 Dividend
TTK Healthcare reported a steady 7% growth in annual revenue from operations, reaching ₹857.28 crore for FY26. Net profit for the year declined to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a high base effect from a ₹19.77 crore land sale profit in the previous year. The Board has recommended a dividend of ₹10 per share (100% of face value). Additionally, the company has reappointed Mr. T T Raghunathan as Executive Chairman for a further five-year term starting November 2026.
முக்கிய அம்சங்கள்
Revenue from operations grew 6.96% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.Net Profit for the year stood at ₹65.68 crore with an EPS of ₹46.48, down from ₹81.66 crore in the previous year.Recommended a final dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.Recognized an exceptional income of ₹350.41 lakhs in Q4 FY26 pertaining to GST refunds from earlier periods.Total Assets increased to ₹1,328.74 crore as of March 31, 2026, up from ₹1,281.19 crore in the previous year.
👀 கவனிக்க வேண்டியவை
The profit decline is primarily due to non-recurring gains in the previous year rather than operational deterioration; investors should focus on the steady revenue growth and consistent dividend payout. Monitor the impact of the new Wage Structure implementation planned for FY 2026-27.
Aarey Drugs Reports FY26 Results; Total Assets Grow 17% to ₹211.24 Cr
Aarey Drugs & Pharmaceuticals Limited reported its audited financial results for the fiscal year ended March 31, 2026, showing a healthy expansion in its balance sheet. Total assets grew to ₹211.24 crore from ₹180.50 crore in the previous year, while total equity increased to ₹143.69 crore. The company received an unmodified audit opinion, although auditors noted that debtor and creditor balances are subject to confirmation. Additionally, the board reviewed the utilization of funds raised through the preferential issue of convertible warrants.
முக்கிய அம்சங்கள்
Total assets increased by 17% year-on-year to ₹211.24 crore as of March 31, 2026.Total equity (Share Capital + Other Equity) rose to ₹143.69 crore, up from ₹133.00 crore in FY25.Current assets, including trade receivables and inventories, reached ₹176.70 crore compared to ₹155.06 crore last year.The company received an unmodified audit opinion, ensuring the reliability of the reported financial figures.Board approved the statement of fund utilization for convertible warrants issued via the preferential route.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming Profit & Loss statement to evaluate margin trends and monitor the 'Emphasis of Matter' regarding the confirmation of debtor balances, which are significant to the current asset base.
TTK Healthcare FY26 Net Profit Drops 19.5% to ₹65.68 Cr; ₹10 Dividend Declared
TTK Healthcare reported a 7% year-on-year growth in revenue from operations to ₹857.28 crore for FY26. However, net profit for the year declined significantly to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to higher expenses and exceptional items. The company recognized a net exceptional charge of ₹7.58 crore related to the incremental impact of new Labour Codes on employee benefits. Despite the profit dip, the board has recommended a dividend of ₹10 per equity share (100% of face value).
முக்கிய அம்சங்கள்
Revenue from operations increased 7% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.Net profit for FY26 fell to ₹65.68 crore, down from ₹81.66 crore in the previous fiscal year.Earnings Per Share (EPS) declined to ₹46.48 from ₹57.79 in the prior year.Recommended a dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.Exceptional items included a ₹7.58 crore charge for Labour Code compliance and a ₹3.50 crore GST refund.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the decline in profitability and EPS suggests margin pressure despite revenue growth. Monitor the impact of the new wage structure and labour codes on future operating margins.
TTK Healthcare FY26 Revenue Rises 7% to ₹857 Cr; Declares ₹10 Dividend per Share
TTK Healthcare reported a steady 7% YoY growth in annual revenue to ₹857.28 crore for FY26. However, Profit After Tax (PAT) declined by 19.5% to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a net exceptional charge of ₹4.07 crore and a high base effect from the previous year's exceptional gains. The company has recommended a dividend of ₹10 per share (100%) and approved the reappointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
முக்கிய அம்சங்கள்
Annual Revenue from Operations increased to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.Net Profit for FY26 stood at ₹65.68 crore, down from ₹81.66 crore in the previous year.Recommended a dividend of ₹10 per equity share of ₹10 each for the financial year ended March 31, 2026.Exceptional items for FY26 included a ₹7.58 crore charge for Labour Code adjustments, partially offset by a ₹3.50 crore GST refund.Executive Chairman T T Raghunathan reappointed for a 5-year term effective November 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should focus on the steady top-line growth while monitoring the impact of rising operational expenses on margins. The consistent dividend payout remains a positive for long-term shareholders.
Sai Parenterals FY26 Revenue Jumps 133% to ₹381 Cr; Targets ₹750 Cr Revenue in FY27
Sai Parenterals reported a transformational FY26 with consolidated revenue growing 133% to ₹381 crore, significantly boosted by the acquisition of Australia-based Noumed Pharmaceuticals. The company is currently executing a ₹440 crore growth capex program, including EU-GMP upgrades in India and a new facility in Adelaide, Australia. Management has issued strong guidance for FY27, targeting ₹750 crore in revenue and 17% EBITDA margins, with FY28 expected to show the full impact of current investments. The integration of Noumed provides access to 451 IP dossiers and major Australian pharmacy networks.
முக்கிய அம்சங்கள்
Consolidated FY26 revenue reached ₹381 crore, up 133% YoY, while standalone PAT grew 64% to ₹17 crore.Management guidance for FY27 targets ₹750 crore revenue and 17% EBITDA margins.Executing a ₹440 crore capex program, including ₹111 crore for India upgrades and ₹311 crore for the Adelaide facility.Acquisition of Noumed Pharmaceuticals adds 451 IP dossiers and distribution access to 2,100 pharmacies in Australia.Vertical integration benefits and internalization of Noumed's manufacturing are expected to drive significant margin expansion in FY28.
👀 கவனிக்க வேண்டியவை
Investors should track the timely commissioning of the Adelaide facility and EU-GMP upgrades in India by Q4 FY27, as these are the primary catalysts for the projected doubling of revenue. The successful integration of Noumed's IP portfolio into the Indian manufacturing base remains a key monitorable for margin improvement.
Share India Securities Credit Rating Downgraded by Acuité; Company Cites Agency Transition
Acuité Ratings has downgraded several debt facilities of Share India Securities to 'Issuer not co-operating' status, including over ₹1,200 crore in Bank Guarantees and ₹150 crore in MLDs. The company has clarified that this downgrade is a result of their decision to transition credit rating services to CRISIL and stop cooperating with Acuité. Share India maintains that many of the facilities rated by Acuité are non-operational or surrendered, and their active ratings with CRISIL remain valid and reaffirmed. This appears to be a procedural conflict between the agency and the company rather than a fundamental credit issue.
முக்கிய அம்சங்கள்
Acuité downgraded ₹1,278 crore of Bank Guarantees from ACUITE A1+ to ACUITE A4+ under 'Issuer not co-operating' status.Proposed Long Term Loans and Secured Overdrafts downgraded to ACUITE BB+ from ACUITE A+.₹150 crore Proposed Principal Protected Market Linked Debentures (PP-MLD) downgraded to ACUITE BB+.Company states it transitioned to CRISIL Ratings Limited and informed Acuité of the same in March 2026.Share India claims the downgraded facilities are largely non-operational or have already been surrendered.
👀 கவனிக்க வேண்டியவை
Investors should focus on the active CRISIL ratings rather than the Acuité downgrade, which appears to be a procedural result of non-cooperation during an agency switch. Monitor for any future updates from CRISIL to ensure credit stability remains intact.
MT Educare Reports Default of ₹32.33 Cr in Borrowings Amid Ongoing Insolvency Process
MT Educare Limited has disclosed a default on principal and interest payments totaling ₹32.33 crores to lenders including Prudence ARC and Axis Bank. The company has been under the Corporate Insolvency Resolution Process (CIRP) since December 16, 2022, following an NCLT order. In addition to direct borrowings, corporate guarantees worth approximately ₹23.99 crores have been invoked against the company. A significant claim of ₹49.72 crores from SVC Bank remains under appeal at the NCLAT after being initially rejected by the NCLT.
முக்கிய அம்சங்கள்
Total outstanding borrowings from banks and financial institutions amount to ₹32.33 crores.Default to Prudence ARC includes ₹16.44 crores in principal and ₹3.75 crores in interest.Default to Axis Bank includes ₹7.65 crores in principal and ₹4.51 crores in interest.Invoked corporate guarantees total ₹23.99 crores for Sri Gayatri Education Society and Lakshya Forum.Company remains under CIRP with a pending NCLAT decision regarding a ₹49.72 crore claim by SVC Bank.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in the middle of insolvency proceedings, which often leads to substantial equity dilution or total loss for retail shareholders. The ongoing legal disputes and defaults indicate a high risk of capital loss.
Sai Parenterals Bags 10-Year Order Worth Rs 104.50 Cr from PILL CORP, Philippines
Sai Parenterals Limited has secured a significant international contract from PILL CORP, Philippines, for the supply of anti-TB products. The contract is valued at USD 11 million, which translates to approximately Rs. 104.50 Crores at an exchange rate of Rs. 95 per USD. This is a long-term agreement spanning 10 years on an exclusivity basis, starting from June 1, 2026. The deal provides long-term revenue visibility and strengthens the company's footprint in the international pharmaceutical market.
முக்கிய அம்சங்கள்
Total contract value of USD 11 million (approximately Rs. 104.50 Crores).10-year exclusive supply agreement for anti-TB products in the Philippines market.Contract execution is set to commence on June 1, 2026.Valuation calculated at a fixed exchange rate of Rs. 95 per USD.The order is from an international entity with no promoter group interest or related party involvement.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for long-term revenue stability; however, they should monitor the execution of periodic purchase orders and the impact of currency fluctuations on margins.
Rajdarshan Industries Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with the statutory auditors issuing an unmodified opinion. The company confirmed the re-appointment of Mr. Anil Jain as the Internal Auditor for the 2026-27 financial year to maintain internal control standards. Additionally, the company is expanding its operational infrastructure by opening a new administrative office in Udaipur effective June 1, 2026. The board meeting concluded on May 26, 2026, after reviewing both standalone and consolidated performance.
முக்கிய அம்சங்கள்
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.Statutory auditors M/s. Ajay Paliwal & Co issued an audit report with an unmodified opinion for FY26.Re-appointed Mr. Anil Jain (Membership No. 406311) as Internal Auditor for the 2026-27 financial year.Announced the opening of a new administrative office at Mumal Tower, Udaipur, effective June 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should examine the full FY26 financial statements to assess the company's revenue growth and profitability trends. The unmodified audit opinion and continuity in internal audit indicate stable corporate governance.
Rajdarshan Industries Reports FY26 Net Loss of ₹17.65 Lakhs as Revenue Declines 63%
Rajdarshan Industries Limited reported a weak financial performance for the fiscal year ended March 31, 2026, with consolidated revenue from operations falling significantly to ₹57.38 Lakhs from ₹157.28 Lakhs in the previous year. The company swung from a net profit of ₹23.49 Lakhs in FY25 to a net loss of ₹17.65 Lakhs in FY26. Total comprehensive income was further impacted by other losses, resulting in a total comprehensive loss of ₹147.96 Lakhs. A significant concern remains regarding ₹3.90 Crores in loans and advances outstanding for over three years for which no provision has been made.
முக்கிய அம்சங்கள்
Consolidated revenue from operations decreased by 63.5% YoY to ₹57.38 Lakhs in FY26.The company reported a consolidated net loss of ₹17.65 Lakhs versus a profit of ₹23.49 Lakhs in FY25.Total comprehensive loss for the year stood at ₹147.96 Lakhs compared to a profit of ₹47.77 Lakhs in the prior year.Management disclosed ₹3.90 Crores in loans and advances outstanding for more than 3 years without provisioning.Announced the opening of a new administrative office in Udaipur effective June 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company has moved into a loss-making position with a sharp decline in core revenue. The lack of provisioning for long-outstanding loans of ₹3.90 Crores is a significant risk factor that could lead to future write-offs.
Hindware Home Innovation FY26 EBITDA Rises 27% to ₹233 Cr; Bathware Debt Reduced to ₹234 Cr
Hindware Home Innovation reported consolidated FY26 revenue of ₹2,510 crore, nearly flat YoY, but saw EBITDA grow 27% to ₹233 crore with margins improving to 9%. The company achieved a turnaround with a PBT of ₹45 crore against a loss of ₹28 crore in FY25. Management has strategically exited loss-making categories like fans and air coolers to focus on high-margin kitchen appliances and water heaters. The Bathware segment remains strong, contributing ₹1,520 crore in revenue with a 10.3% EBITDA margin.
முக்கிய அம்சங்கள்
Consolidated EBITDA grew 27% YoY to ₹233 crore with margins expanding by 200 bps to 9% in FY26.Net bank debt in the Bathware division decreased by ₹74 crore to ₹234 crore during the fiscal year.Working capital cycle improved to 89 days from 103 days, driven by better inventory and receivables management.Management guided for 15-20% revenue growth in the Bathware segment for FY27 with further margin improvement.Discontinued low-margin categories including fans, air purifiers, and furniture fittings to sharpen focus on kitchen appliances.
👀 கவனிக்க வேண்டியவை
Investors should note the significant margin expansion and debt reduction as the company exits non-core, loss-making segments. The strong 15-20% growth guidance for the core Bathware business makes it a key stock to watch for recovery and growth.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
